chromodomain helicase DNA binding protein 1 likeGenealiases: ALC1 · CHDL
Q-omics provides the consensus-scored CHD1L profile across patient tissues and cancer cell-line models. CHD1L expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, CHD1L is differentially expressed in 15, with the highest sampling consensus in HNSC. Additionally, CHD1L protein abundance shows 27,064 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight ACC, HNSC, and LSCC as cancer lineages where CHD1L shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CHD1L — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CHD1L survival associations across molecular data types. CHD1L RNA expression shows survival associations in the most cancer types (25), followed by mutation status (6) and mass-spec protein abundance (10). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CHD1L RNA expression–survival associations across cancer types. High CHD1L expression shows unfavorable associations in ACC, KIRP, LIHC, LUAD, KIRC and KICH. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for CHD1L RNA expression.
This table summarizes CHD1L tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 15, while mass-spec protein shows differences in 10. The strongest signals are observed in HNSC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for CHD1L. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CHD1L shows lower tumor expression in KICH and higher tumor expression in HNSC, LUAD, LIHC, STAD and BLCA. The HNSC box plot shows higher CHD1L RNA expression in tumor versus normal tissue (log2 FC = +0.891, t-test p < 0.001).
This table shows molecular features associated with CHD1L in patient tissues and cancer cell lines. In patient samples, CHD1L shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, CHD1L RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OVARY, while CRISPR and shRNA rows add functional-dependency signals in PANCREAS and SOFT_TISSUE.
